ReviewJournal of clinical immunology2018

Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials.

Stephen Jolles et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.